Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Corporate Update (Aug 31, 2026)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed August 31, 2026
Period End
August 31, 2026
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Aug ’21Aug ’21
  3. Material agreement8-K · Mar ’23Mar ’23
  4. Material agreement8-K · Jan ’26Jan ’26

Summary

Summary of the 8-K filed August 31, 2026. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported in an Item 8.01 Other Event filing dated August 31, 2026 that it has entered into a voluntary agreement with the U.S. government to expand access to its medicines and lower costs for American patients.

As part of the agreement, BridgeBio will expand state Medicaid access to its currently marketed medicine, Attruby (acoramidis), via the GENEROUS Model. The company states that it does not expect to be subject to future pricing mandates, and that the specific terms of the agreement remain confidential. The company also expects that its pricing commitment for future medicines under the agreement will exclude medicines approved exclusively for orphan indications.

The filing states that BridgeBio will continue to offer Attruby via Medicare Part D without any future pricing mandates, and that the agreement has no impact on its ForgingBridges copay assistance program, which can reduce out-of-pocket costs to as little as $0a per month for qualifying patients. The filing's forward-looking statements flag risks, including that the agreement may be implemented or interpreted differently than expected, that additional pricing mandates could be imposed, and that government pricing or reimbursement policies could change. The company's pipeline referenced in the press release includes BBP-418 (PDUFA date with Priority Review: November 27, 2026), encaleret (PDUFA date with Priority Review: May 7, 2027), and infigratinib for achondroplasia, which is under FDA review.

Key Highlights

  1. BridgeBio entered a voluntary agreement with the U.S. government to expand access to its medicines and lower costs for American patients.
  2. Medicaid access to Attruby (acoramidis) will be expanded in states via the GENEROUS Model.
  3. BridgeBio states it expects not to be subject to future pricing mandates, and will continue offering Attruby via Medicare Part D without any future pricing mandates.
  4. The company expects its pricing commitment for future medicines to exclude medicines approved exclusively for orphan indications.
  5. The specific terms of the agreement remain confidential.
  6. The agreement has no impact on the ForgingBridges copay assistance program, which can reduce out-of-pocket costs to as little as $0 per month for qualifying patients.
  7. Pipeline milestones cited include BBP-418 (PDUFA November 27, 2026) and encaleret (PDUFA May 7, 2027), both with Priority Review.

Frequently Asked Questions

  1. What did BridgeBio agree to with the U.S. government?

    BridgeBio entered a voluntary agreement to expand access to its medicines and lower drug costs for Americans. The agreement includes expanding state Medicaid access to Attruby via the GENEROUS Model. The specific terms remain confidential.

  2. Will BridgeBio be subject to future pricing mandates?

    The company states it does not expect to be subject to future pricing mandates. The filing also lists risks that additional pricing mandates, requirements, or restrictions could still be imposed despite this expectation.

  3. Does the agreement affect patients' out-of-pocket costs?

    The agreement has no impact on the ForgingBridges copay assistance program, which the company says can reduce out-of-pocket costs to as little as $0 per month for qualifying patients.

  4. How does the agreement treat orphan-indication medicines?

    BridgeBio expects its pricing commitment for future medicines under the agreement to exclude medicines approved exclusively for orphan indications.

  5. What are the key risks cited in the filing?

    The forward-looking statements cite risks including that the agreement may be implemented, interpreted, or applied differently than expected, that government pricing or reimbursement policies may change, that the agreement may not produce the anticipated access or affordability benefits, and macroeconomic and geopolitical factors.